PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28784305-8	2017	After hepatic I/R injury, WT and NLRC5-/- mice pre-treated with DEX exhibited attenuated histological disruption, and reduced pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, IL-1beta and inducible nitric oxide synthase (iNOS), which was associated with the inactivated NF-kappaB pathway.	Dexmedetomidine	64-67	interleukin 1 beta	Mus musculus	225-233	
30071186-7	2018	RESULTS: We found that Dex exerted a potent anti-inflammatory effect by reducing the expression of M1 marker genes such as tumor necrosis factor alpha (P < 0.05), interleukin-1beta (IL-1beta) (P < 0.001) and IL-6 (P < 0.001).	Dexmedetomidine	23-26	interleukin 1 beta	Mus musculus	166-183	
30071186-7	2018	RESULTS: We found that Dex exerted a potent anti-inflammatory effect by reducing the expression of M1 marker genes such as tumor necrosis factor alpha (P < 0.05), interleukin-1beta (IL-1beta) (P < 0.001) and IL-6 (P < 0.001).	Dexmedetomidine	23-26	interleukin 1 beta	Mus musculus	185-193	
29269298-9	2018	RESULTS: Dexmedetomidine at 20 mug/kg significantly attenuated pancreatic pathological injury, reduced serum levels of amylase, lipase, IL-1beta, IL-6, and tumor necrosis factor (TNF)-alpha, and decreased the expression of MPO in pancreatic tissue in both mouse models of pancreatitis.	Dexmedetomidine	9-24	interleukin 1 beta	Mus musculus	136-144	
29269298-10	2018	In addition, dexmedetomidine at 20 mug/kg significantly down-regulated the expression of NLRP3, pro-IL-1beta, and IL-1beta in pancreatic tissue, but up-regulated the expression of NET in both mouse models.	Dexmedetomidine	13-28	interleukin 1 beta	Mus musculus	100-108	
29269298-10	2018	In addition, dexmedetomidine at 20 mug/kg significantly down-regulated the expression of NLRP3, pro-IL-1beta, and IL-1beta in pancreatic tissue, but up-regulated the expression of NET in both mouse models.	Dexmedetomidine	13-28	interleukin 1 beta	Mus musculus	114-122	
28224201-11	2017	DEX suppressed the infiltration of macrophages and T cells into the kidneys following cisplatin treatment, which was involved in the inhibition of NF-kappaB activation and decreased expression of TNF-alpha, IL-1beta, IL-6, and MCP-1.	Dexmedetomidine	0-3	interleukin 1 beta	Mus musculus	207-215	
26702389-6	2015	Our results provided evidence that Dex treatment attenuated LPS-activated NF-kappaB p65 activation, as well as the production of tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta at the level of both mRNA and protein in spleen.	Dexmedetomidine	35-38	interleukin 1 beta	Mus musculus	177-194	
26211495-8	2015	The results showed that pretreatment with Dex considerably reduced neutrophil infiltration and pulmonary edema, and significantly reduced protein concentrations in the BALF, as well as suppressed LPS-induced elevation of proinflammatory cytokines (TNF-alpha and IL-1beta) in the serum.	Dexmedetomidine	42-45	interleukin 1 beta	Mus musculus	262-270	
34782991-13	2022	RESULTS: The results showed that low doses of Dex suppress NLRP3 and interleukin-1beta in both terms.	Dexmedetomidine	46-49	interleukin 1 beta	Mus musculus	69-86	
33821300-5	2021	RESULTS: DEX significantly inhibited LPS-induced increases in the lung weight/body weight ratio and lung wet/dry weight ratio, decreased inflammatory cell infiltration, and decreased the production of proinflammatory factors, such as interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF-alpha)in the lungs.	Dexmedetomidine	9-12	interleukin 1 beta	Mus musculus	234-251	
24803295-11	2014	Preemptive administration of dexmedetomidine significantly attenuated the cytokine response after lipopolysaccharide (LPS) induced endotoxemia (TNF-alpha, IL-1beta, IL-6, P<0.01, respectively).	Dexmedetomidine	29-44	interleukin 1 beta	Mus musculus	155-163	
19181340-8	2009	The effects of dexmedetomidine on COX-2 expression and the production of PGE2, TNF-alpha, IL-1beta, IL-6, and IL-10 paralleled the effects of dexmedetomidine on iNOS.	Dexmedetomidine	15-30	interleukin 1 beta	Mus musculus	90-98	
34747306-9	2021	The MPO activity and inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, and NLR family pyrin domain-containing 3) levels were also significantly reduced after DEX treatment compared with those in the ALI mice.	Dexmedetomidine	180-183	interleukin 1 beta	Mus musculus	74-91